State of Alaska Department of Revenue Has $2.22 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

State of Alaska Department of Revenue increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 213.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 46,508 shares of the biopharmaceutical company's stock after purchasing an additional 31,670 shares during the period. State of Alaska Department of Revenue's holdings in Halozyme Therapeutics were worth $2,222,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Congress Asset Management Co. lifted its position in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock worth $139,298,000 after buying an additional 1,988,238 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Halozyme Therapeutics by 698.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock valued at $13,756,000 after purchasing an additional 251,711 shares during the period. Boston Trust Walden Corp raised its holdings in shares of Halozyme Therapeutics by 54.0% in the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company's stock valued at $39,073,000 after purchasing an additional 239,321 shares during the period. South Street Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $9,812,000. Finally, Hantz Financial Services Inc. bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $9,260,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded down $0.32 on Friday, reaching $58.29. 1,000,407 shares of the company's stock were exchanged, compared to its average volume of 1,263,674. The company has a fifty day moving average of $52.50 and a 200-day moving average of $54.50. Halozyme Therapeutics, Inc. has a twelve month low of $35.23 and a twelve month high of $65.53. The company has a market capitalization of $7.42 billion, a price-to-earnings ratio of 19.30, a PEG ratio of 0.44 and a beta of 1.25. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of research analyst reports. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Wells Fargo & Company dropped their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, February 4th. Finally, JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $60.89.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.